Senores Pharmaceuticals Limited is a global, research-driven pharmaceutical company specializing in developing and manufacturing complex and specialty products for regulated markets like the US, Canada, and the UK, with a presence in 43 emerging markets. The company focuses on underpenetrated and high-demand molecules, leveraging strong R&D capabilities to deliver critical care injectables, APIs, and diverse dosage forms. Trusted by partners like Prasco LLC, Sun Pharma, and Cipla USA, Senores stands out for quality, innovation, and a robust pipeline of complex pharmaceutical products.
Issue size
Funds Raised in the IPO
Amount
Overall
₹TBA
Fresh Issue
₹TBA
Utilisation of proceeds
Purpose
INR crores (%)
Investment in Subsidiary Havix for capital expenditure and manufacturing facility
107.00 (35.26%)
Repayment/pre-payment of certain borrowings
73.48 (24.22%)
Investment in Subsidiary Havix for repayment of borrowings
20.22 (6.66%)
Capital requirements
43.26 (14.26%)
Investment in Subsidiaries (SPI and Ratnatris) for working capital requirements
59.48 (19.60%)
Financials
Financial Year Ended
March 2022
March 2023
March 2024
September 2024
Total Assets
59.15
131.05
621.88
678.08
Revenue
14.63
39.02
217.34
183.35
Profit After Tax
0.99
8.43
32.71
23.94
Strengths
Expanding manufacturing for sterile injections.
Reducing operational debt through funding.
Strategic fund allocation to subsidiaries.
Focus on growth through acquisitions.
Risks
High dependence on borrowed funds.
Regulatory hurdles in manufacturing.
Market volatility impacts growth plans.
Challenges in fund utilization across subsidiaries.